Sentinel lymph node (SLN) concept in cervical cancer: Current limitations and unanswered questions.
Cervical cancer
Low volume disease
Pathologic evaluation
Sentinel lymph node
Ultrastaging
Journal
Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
02
09
2018
revised:
02
10
2018
accepted:
05
10
2018
pubmed:
16
10
2018
medline:
5
2
2019
entrez:
16
10
2018
Statut:
ppublish
Résumé
Sentinel lymph node (SLN) biopsy has been increasingly used in the management of early-stages cervical cancer instead of systematic pelvic lymph node dissection (PLND). The aim of this article is to give a critical overview of key aspects related to this concept, such as a necessity for reliable detection of micrometastases (MIC) in SLN and the requirements for SLN pathologic ultrastaging, low accuracy of intraoperative detection of SLN involvement, and still a limited evidence of oncological safety of the replacement of PLND by SLN biopsy only in ≥IB1 tumours due to unknown risk of MIC in non-SLN pelvic lymph nodes in patients with negative SLN, and absence of any prospective evidence.
Identifiants
pubmed: 30318103
pii: S0090-8258(18)31286-1
doi: 10.1016/j.ygyno.2018.10.007
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
202-207Informations de copyright
Copyright © 2018 Elsevier Inc. All rights reserved.